Using the TCGA database, we analyzed CCL26 mRNA levels across various normal and corresponding tumor tissues (Figure 2A), and found that the mRNA expression of CCL26 expression was abnormally high in several cancers compared to normal tissues, particularly in cholangiocarcinoma, colorectal, esophageal squamous, head and neck squamous, hepatocellular, lung, and gastric carcinomas and it was markedly downregulated in bladder uroepithelial, renal, and gastric cancers. Here, CCL26 is linked to cholangiocarcinoma.